pathologist
h
e
like
clinician
h
p
histori
physic
basic
exam
perform
everi
patient
specimen
form
cornerston
diagnosi
howev
pathologist
longer
limit
h
e
wide
varieti
special
studi
avail
evalu
patholog
process
simpl
histochem
stain
global
gene
express
pattern
pathologist
clinic
cell
biologist
familiar
type
special
studi
avail
import
initi
process
gross
specimen
may
limit
type
studi
perform
almost
histochem
stain
suitabl
formalinfix
tissu
common
stain
use
list
tabl
howev
numer
type
stain
modif
use
pathologist
must
awar
individu
laboratori
practic
webpath
section
univers
utah
site
http
librarymedutaheduwebpath
use
descript
special
stain
illustr
photograph
develop
method
detect
antigen
tissu
section
antibodi
major
advanc
surgic
patholog
immunohistochem
ihc
studi
frequent
use
follow
purpos
classif
tumor
eg
carcinoma
vs
lymphoma
b
cell
vs
cell
lymphoma
identif
situ
lesion
vs
invas
carcinoma
eg
myoepitheli
marker
breast
cancer
basal
cell
marker
prostat
prognost
factor
eg
glioblastoma
predict
factor
guid
specif
therapi
eg
ckit
estrogen
progesteron
receptor
identif
extracellular
materi
eg
microglobulin
amyloid
identif
infecti
agent
eg
cmv
hsv
use
immunohistochemistri
differenti
diagnosi
gener
examin
h
estain
slide
ihc
use
gain
evid
diagnost
possibl
troll
case
immunohistochemistri
laboratori
order
numer
antibodi
studi
without
clear
reason
mind
like
lead
misguid
diagnosi
due
aberr
immunoreact
provid
unexpect
correct
diagnosi
panel
absolut
rule
immunoreact
cell
tissu
aberr
immunoreact
loss
immunoreact
occasion
observ
antibodi
either
due
biolog
variabl
eg
occasion
keratinposit
melanoma
technic
factor
eg
impur
antibodi
crossreact
antigen
failur
preserv
antigen
thu
immunohistochem
marker
use
effect
panel
marker
interpret
base
immunohistochem
profil
slide
immunohistochemistri
tissu
often
dislodg
normal
glass
slide
treatment
requir
ihc
thu
slide
must
coat
eg
glue
polyllysin
gelatin
albumin
special
commerci
slide
must
use
slide
prepar
anoth
laboratori
type
glass
slide
use
must
specifi
factor
affect
immunogen
numer
variabl
affect
antigen
common
list
laboratori
must
optim
procedur
antibodi
use
studi
tissu
slide
prepar
routin
fashion
laboratori
must
interpret
caution
type
fix
fix
destroy
antigen
eg
bouin
diminish
er
immunoreact
keratin
well
preserv
studi
base
formalinfix
tissu
result
assum
equival
fix
length
time
fixat
formalin
caus
protein
crosslink
antigen
gener
decreas
fixat
time
hour
extent
effect
revers
use
antigen
retriev
method
antigen
also
reduc
tissu
fix
short
period
eg
less
hour
prior
decalcif
hydrochlor
acid
decreas
antigen
epitop
predominantli
nuclear
other
predominantli
cytoplasm
decalcifi
agent
use
edta
alter
immunogen
decreas
estrogen
receptor
er
progesteron
receptor
pr
tumor
cell
h
blood
group
affect
calcitonin
chromogranin
hmb
thyroglobulin
prostatespecif
antigen
psa
keratin
ck
b
blood
group
other
temperatur
bake
slide
length
time
sinc
glass
slide
cut
immunoreact
major
antigen
declin
day
week
potenti
complet
loss
one
month
loss
may
due
exposur
tissu
air
oxid
amino
acid
immunogen
tissu
deeper
block
preserv
mani
year
antigen
retriev
method
complet
restor
antigen
old
slide
coat
slide
paraffin
store
slide
nitrogen
desicc
andor
store
lower
temperatur
partial
preserv
antigen
howev
studi
perform
newli
cut
slide
possibl
antigen
retriev
procedur
eg
proteolysi
heat
microwav
steam
special
incub
fluid
extent
method
revers
effect
formalin
fixat
variabl
effect
observ
differ
antibodi
type
antibodi
polyclon
vs
monoclon
vs
mixtur
differ
monoclon
epitop
detect
mous
vs
rabbit
differ
result
obtain
differ
antibodi
protein
differ
commerci
sourc
antibodi
incub
time
incub
temperatur
dilut
antibodi
method
signal
amplif
control
essenti
appropri
interpret
immunohistochem
studi
ensur
step
complic
procedur
perform
adequ
posit
control
consist
tissu
known
immunoreact
includ
time
antibodi
use
test
case
intern
posit
control
alway
evalu
present
control
techniqu
use
also
antigen
tissu
investig
immunoperoxidas
tabl
list
normal
cell
gener
immunoreact
antibodi
laboratori
use
vimentin
control
immunogen
almost
tissu
demonstr
posit
given
wide
nonspecif
distribut
vimentin
smooth
muscl
alpha
actin
may
use
context
pericyt
vascular
smooth
muscl
myoepitheli
cell
present
tissu
immunoreact
exampl
intern
control
normal
nerv
melanocyt
langerhan
cell
epidermi
cartilag
myoepitheli
cell
skin
adnexa
estrogen
progesteron
receptor
normal
lumin
cell
duct
lobul
breast
neg
control
usual
consist
replac
primari
antibodi
nonimmun
anim
serum
dilut
concentr
primari
antibodi
posit
reaction
present
multipl
primari
antibodi
use
reactiv
differ
target
antigen
may
serv
neg
control
although
best
neg
control
would
use
antibodi
preabsorb
target
antigen
rare
practic
diagnost
laboratori
diagnost
slide
also
evalu
intern
neg
control
aberr
immunoreact
tissu
posit
indic
immunoreact
nonspecif
studi
use
interpret
follow
featur
must
taken
consider
evalu
studi
locat
immunoreact
antigen
present
specif
site
antigen
may
present
one
locat
extracellular
nonspecif
posit
suspect
immunoreact
present
atyp
locat
background
suspect
nonspecif
posit
normal
cell
noncellular
compon
posit
occur
suboptim
perform
assay
suboptim
antibodi
edg
artifact
antibodi
pool
edg
hole
tissu
true
posit
also
present
center
tissu
necrosi
crush
cell
nonspecif
posit
seen
disrupt
cell
although
keratin
gener
reliabl
necrot
tumor
marker
gener
interpret
inappropri
locat
eg
cytoplasm
instead
nucleu
occasion
er
pr
present
cytoplasm
instead
nucleu
interpret
posit
result
plasma
cell
larg
amount
cytoplasm
immunoglobulin
crossreact
mani
antibodi
rare
case
immunoreact
unusu
locat
diagnost
import
cytoplasm
instead
nuclear
posit
hepatocellular
carcinoma
cytoplasm
membran
instead
nuclear
posit
trabecular
hyalin
adenoma
thyroid
scleros
hemangioma
lung
betacatenin
nuclear
instead
cytoplasm
posit
solid
pseudopapillari
tumor
pancrea
pancreatoblastoma
nuclear
cytoplasm
posit
seen
major
colon
carcinoma
nuclear
posit
present
endometrioid
endometri
carcinoma
case
desmoidtyp
fibromatosi
alk
pattern
immunoreact
correl
differ
type
chromosom
transloc
anaplast
larg
cell
lymphoma
npm
nucleophosmin
shuttl
cytoplasm
nucleu
mutat
occur
adult
aml
caus
aberr
cytoplasm
express
npm
npmc
aml
case
specif
gene
express
profil
distinct
clinic
prognost
featur
exampl
normal
locat
antigen
shown
figur
identif
immunoreact
cell
immunoreact
tumor
cell
must
distinguish
immunoreact
normal
entrap
cell
eg
desmin
skelet
muscl
cell
infiltr
tumor
langerhan
cell
tumor
smooth
muscl
alpha
actin
blood
vessel
etc
plasma
cell
larg
amount
cytoplasm
immunoglobulin
react
nonspecif
mani
antibodi
pathologist
signific
immunoreact
vari
type
lesion
antibodi
specif
assay
strong
posit
major
cell
easili
interpret
posit
number
posit
cell
decreas
intens
immunoreact
weaken
lower
threshold
posit
result
becom
difficult
determin
time
alkalin
phosphatas
chromogen
red
color
fade
time
dab
brown
color
perman
problem
evalu
current
patholog
specimen
howev
slide
review
period
time
chromogen
may
fade
posit
result
may
appear
neg
follow
tabl
includ
inform
literatur
well
person
experi
staff
brigham
women
hospit
mani
differ
specif
antibodi
laboratori
assay
criteria
consid
result
posit
result
may
vari
differ
institut
result
divid
five
categori
gener
marker
four
categori
hematopatholog
marker
note
refer
number
tumor
report
posit
number
cell
posit
within
tumor
tabl
actual
marker
use
evalu
case
depend
upon
differenti
diagnosi
base
h
e
appear
case
initi
panel
often
use
typic
case
suggest
marker
list
would
use
case
marker
includ
indic
would
use
distinguish
tumor
list
tabl
posit
defin
presenc
immunoreact
cell
neg
absenc
immunoreact
cell
unfortun
posit
also
use
studi
mean
absenc
immunoreact
find
support
diagnosi
exampl
absenc
report
posit
result
pancreat
carcinoma
marker
absent
major
tumor
method
report
result
becom
confus
posit
neg
depend
expect
diagnosi
prefer
report
find
posit
immunoreact
present
neg
immunoreact
absent
interpret
support
support
diagnos
differenti
diagnosi
combin
two
cytokeratin
found
use
divid
carcinoma
four
main
group
tabl
commonli
use
antibodi
includ
show
differ
within
group
use
addit
antibodi
depend
specif
differenti
diagnosi
small
blue
cell
tumor
see
tabl
see
tabl
nasopharyng
carcinoma
posit
mani
case
asian
north
african
patient
less
commonli
us
patient
associ
ebv
ebv
demonstr
situ
hybrid
pcr
occasion
immunohistochemistri
carcinoma
also
posit
broadspectrum
keratin
pank
c
dendrit
cell
present
may
posit
breast
basallik
carcinoma
spindl
cell
metaplast
carcinoma
squamou
cell
carcinoma
papillari
carcinoma
subtyp
may
also
less
typic
keratin
subset
detect
detect
b
welland
moder
differenti
ductal
carcinoma
carcinoma
special
type
except
medullari
posit
hormon
receptor
poorli
differenti
carcinoma
metaplast
carcinoma
medullari
carcinoma
usual
neg
welland
moder
differenti
lobular
carcinoma
almost
alway
posit
er
usual
posit
pr
poorli
differenti
lobular
carcinoma
may
neg
marker
c
nonmucin
bronchioloalveolar
carcinoma
immunophenotyp
similar
lung
adenocarcinoma
mucin
bal
like
posit
posit
posit
posit
less
like
posit
posit
secretori
meningioma
frequent
posit
cea
wherea
subtyp
usual
neg
cea
major
type
meningioma
posit
pr
incud
meningioma
male
e
mix
tumor
pleomorph
adenoma
occur
frequent
salivari
gland
also
aris
soft
tissu
myoepitheli
tumor
soft
tissu
tumor
similar
immunophenotyp
keratin
pank
ema
present
major
tumor
frequent
express
marker
associ
myoepitheli
cell
eg
calponin
gfap
sma
howev
seen
less
frequent
compar
salivari
tumor
f
chromophob
renal
cell
carcinoma
may
posit
type
neg
rare
colon
carcinoma
either
posit
neg
rare
although
major
colon
carcinoma
posit
almost
one
third
colon
carcinoma
microsatellit
instabl
msih
posit
neg
see
tabl
signific
immunoreact
membran
pattern
major
cell
g
plasma
cell
lymphoma
may
posit
ewe
pnet
desmoplast
small
round
cell
tumor
rhabdomyosarcoma
neuroblastoma
medulloblastoma
characterist
cytogenet
chang
see
tabl
em
advantag
immunohistochemistri
evalu
childhood
small
round
blue
cell
tumor
initi
panel
keratin
lca
addit
studi
may
help
depend
histolog
appear
result
initi
studi
keratin
posit
may
present
epithelioid
angiosarcoma
cellular
dermatofbroma
may
show
focal
desmin
immunoreact
posit
j
alveolar
soft
part
sarcoma
character
transloc
fuse
transcript
factor
gene
novel
gene
call
aspl
sarcoma
demonstr
nuclear
immunoreact
rare
pediatr
renal
tumor
transloc
immunoreact
present
tumor
normal
tissu
characterist
cytoplasm
crystal
compos
monocarboxyl
transport
chaperon
howev
protein
found
mani
cell
type
specif
tumor
k
keratin
ema
posit
usual
focal
monophas
synovi
sarcoma
l
posit
glandular
area
synovi
sarcoma
less
spindl
cell
area
immunohistochem
pattern
epithelioid
mesothelioma
given
separ
tabl
n
may
posit
minor
epithelioid
compon
sarcomatoid
mesothelioma
gener
neg
spindl
cell
secretori
meningioma
typic
cytokeratin
posit
neg
also
posit
cea
subtyp
gener
neg
keratin
howev
malign
meningioma
may
posit
keratin
p
squamou
cell
carcinoma
spindl
cell
morpholog
gener
strongli
posit
less
commonli
ema
spindl
cell
carcinoma
breast
often
express
marker
express
myoepitheli
cell
basal
keratin
includ
cytokeratin
includ
group
detect
pank
smooth
muscl
alpha
actin
poorli
differenti
carcinoma
spindl
cell
morpholog
may
show
focal
posit
keratin
ema
q
dermatofibroma
may
weak
peripher
posit
distinguish
strong
diffus
posit
dfsp
r
sarcoma
eg
mpnst
posit
marker
help
distinguish
benign
malign
lipomat
tumor
pathologist
frequent
receiv
specimen
metastat
tumor
often
site
origin
known
clinician
inform
provid
pathologist
good
clinic
histori
frequent
success
correct
classif
batteri
studi
pattern
gener
help
narrow
potenti
site
origin
carcinoma
see
tabl
addit
studi
use
identifi
specif
type
carcinoma
import
tumor
identifi
specif
therapeut
treatment
cure
palliat
lung
carcinoma
also
posit
thyroglobulin
neg
highli
effect
treatment
cure
radioact
iodin
thyroid
medullari
carcinoma
calcitonin
famili
import
counsel
famili
member
palli
treatment
tumordirect
radionucleotid
inhibin
inhibin
specif
trophoblast
tumor
unlik
neg
chemotherapi
possibl
cure
trastuzumab
herceptin
monoclon
antibodi
direct
receptor
b
imatinib
mesyl
small
molecul
tyrosin
kinas
inhibitor
use
cml
ph
gist
kit
protein
encod
ckit
protooncogen
transmembran
receptor
protein
tyrosin
kinas
activ
mutat
protein
may
may
respond
therapi
imatinib
mutat
render
kit
independ
ligand
scf
stem
cell
factor
found
gist
aml
germ
cell
tumor
system
mastocytosi
wildtyp
kit
kit
mutat
juxtamembran
domain
intracellular
segment
transmembran
tyrosin
kinas
domain
found
gist
sensit
imatinib
tumor
type
associ
mutat
enzymat
domain
alter
protein
gener
sensit
imatinib
c
gefitinib
iressa
tyrosin
kinas
inhibitor
effect
small
subset
lung
adenocarcinoma
specif
activ
mutat
carcinoma
may
express
unusu
keratin
subtyp
neg
tri
keratin
type
eg
pattern
may
help
determin
like
site
origin
noncarcinoma
epithelioid
appear
strongli
express
keratin
eg
epithelioid
angiosarcoma
epithelioid
sarcoma
mesothelioma
melanoma
protein
strongli
posit
vast
major
melanoma
carcinoma
especi
breast
sarcoma
also
posit
addit
marker
may
requir
express
epithelioid
melanoma
may
focal
absent
nonepithelioid
melanoma
eg
spindl
cell
desmoplast
melanoma
leukocyt
common
antigen
lca
present
almost
nonhodgkin
lymphoma
may
absent
anaplast
larg
cell
lymphoma
lymphoma
keratin
neg
may
express
ema
tumor
posit
alk
hormon
receptor
routin
determin
invas
breast
carcinoma
dci
er
pr
weak
prognost
marker
use
predict
likelihood
respons
hormon
therapi
mani
differ
method
current
use
report
result
ihc
studi
er
pr
one
method
use
multipl
studi
allr
score
method
tabl
patient
carcinoma
score
cell
intermedi
intens
cell
weak
intens
improv
diseasefre
surviv
treat
endocrin
therapi
patient
carcinoma
total
score
weakli
posit
cell
surviv
rate
similar
erneg
carcinoma
total
score
dci
case
posit
er
use
method
score
women
erposit
dci
shown
experi
fewer
local
recurr
contralater
recurr
distant
recurr
treat
tamoxifen
nsabp
studi
optim
ihc
use
newer
antigen
retriev
method
carcinoma
score
therefor
mani
laboratori
report
result
posit
neg
valu
subdivid
case
percent
posit
cell
hscore
imag
analysi
either
prognosi
predict
respons
tamoxifen
demonstr
intens
immunoreact
difficult
evalu
case
show
strong
reactiv
optim
assay
method
carcinoma
show
consider
variabl
intens
possibl
method
report
result
shown
tabl
system
use
report
progesteron
receptor
result
use
er
pr
may
help
determin
likelihood
respons
tamoxifen
shown
data
use
biochem
assay
tabl
presum
presenc
erregul
gene
product
pr
predict
intact
er
regulatori
pathway
recent
nation
guidelin
report
er
pr
releas
consult
addit
inform
perform
interpret
studi
hammond
et
fals
neg
result
lesser
extent
fals
posit
result
also
problem
fals
neg
result
may
due
larg
number
caus
includ
low
sensit
assay
error
perform
assay
delay
fixat
tissu
overor
underfix
tissu
overh
tissu
eg
cauteri
surgeri
decalcif
tissu
case
fals
neg
suspect
normal
breast
tissu
also
neg
case
assay
repeat
block
differ
block
case
block
anoth
case
avail
normal
tissu
remain
neg
possibl
loss
antigen
tissu
mention
report
fals
posit
result
quit
unusu
antibodi
crossreact
antigen
entrap
normal
duct
lobul
misinterpret
carcinoma
difficult
issu
dci
duct
lobul
may
partial
involv
dci
control
place
slide
misinterpret
carcinoma
scleros
adenosi
myofibroblastoma
benign
lesion
misinterpret
invas
carcinoma
immunoreact
score
system
tabl
recommend
expert
panel
panel
suggest
cytoplasm
posit
obscur
membran
pattern
repeat
assay
perform
fish
normal
duct
lobul
show
definit
posit
repeat
assay
case
invas
carcinoma
area
invas
score
case
associ
dci
show
stronger
immunoreact
fixat
must
neutral
buffer
formalin
ideal
hour
excis
least
hour
needl
biopsi
howev
effect
longer
fixat
shown
unstain
slide
use
prepar
week
earlier
loss
antigen
shown
antigen
specif
membran
immunoreact
score
mark
cytoplasm
immunoreact
may
make
interpret
difficult
fish
studi
may
prefer
case
carcinoma
protein
overexpress
gene
amplifi
case
protein
overexpress
occur
due
mechan
case
may
gene
amplif
without
protein
overexpress
gener
respons
herceptin
alon
patient
cancer
show
gene
amplif
fish
patient
respond
gene
amplifi
therefor
fish
studi
may
help
case
posit
difficult
interpret
case
eg
variabl
posit
cytoplasm
posit
welland
moder
differenti
lobular
carcinoma
rare
posit
howev
case
may
edg
enhanc
individu
tumor
cell
may
difficult
interpret
fish
studi
may
help
rare
case
dci
overexpress
accompani
invas
carcinoma
sourc
potenti
fals
posit
result
ihc
fish
myoepitheli
marker
use
evalu
breast
lesion
show
focal
diffus
posit
myoepitheli
marker
protein
cytokeratin
eg
recommend
identifi
myoepitheli
cell
fewer
myoepitheli
cell
posit
lumin
cell
also
posit
good
gener
marker
myoepitheli
cell
particularli
help
case
promin
myofibroblast
eg
scleros
lesion
blood
vessel
close
appos
tumor
cell
eg
papillari
frond
papillari
dci
case
sma
may
posit
myoepitheli
cell
case
paget
diseas
nippl
associ
dci
deeper
breast
involv
lactifer
sinus
half
also
area
invas
rare
case
may
difficult
interpret
due
absenc
associ
diseas
breast
initi
biopsi
shallow
case
paget
cell
may
take
melanin
may
difficult
distinguish
melanoma
toker
cell
present
nippl
epidermi
nippl
ck
posit
neg
paget
diseas
vulva
perian
region
similar
distribut
ie
tumor
cell
present
intact
basement
membran
overli
normal
epiderm
layer
tumor
cell
differ
origin
initi
panel
addit
antibodi
studi
base
find
necessari
see
metastat
lobular
carcinoma
breast
morpholog
resembl
primari
signet
ring
cell
gastric
carcinoma
typic
lack
ecadherin
express
addit
lobular
breast
carcinoma
clinic
occult
present
distant
metastas
mani
year
initi
present
signet
ring
cell
associ
breast
carcinoma
commonli
central
mucin
vacuol
targetoid
appear
cell
gastric
signet
ring
cell
usual
mani
small
vacuol
give
cytoplasm
foami
appear
cell
b
criteria
reliabl
distinguish
two
carcinoma
howev
presenc
first
type
signet
ring
cell
biopsi
gastrointestin
tract
rais
possibl
metastat
breast
carcinoma
major
lobular
breast
carcinoma
er
posit
reliabl
marker
exclud
gastric
carcinoma
minor
erneg
case
pr
gcdfp
hep
par
may
help
marker
see
tabl
see
ck
ck
keratin
may
detect
best
pank
includ
ck
includ
ck
antibodi
specif
keratin
epithelioid
myofibroblastoma
close
resembl
invas
lobular
carcinoma
case
carcinoma
strongli
posit
typic
keratin
also
posit
er
pr
lack
found
half
pancreat
carcinoma
highli
suggest
primari
site
publish
tabl
posit
result
absenc
posit
tabl
posit
signifi
carcinoma
show
immunoreact
see
tabl
see
tabl
see
tabl
see
tabl
fish
use
identifi
germ
cell
tumor
metastas
podoplanin
strongli
express
seminoma
itgcn
also
express
lymphat
endothelium
epithelioid
mesothelioma
hemangioblastoma
see
tabl
tabl
c
antibodi
posit
adren
cortic
carcinoma
anoth
antibodi
antigen
posit
adren
cortic
carcinoma
clear
cell
renal
cell
carcinoma
metastat
adren
sometim
confus
adren
cortic
tumor
thu
older
term
clear
cell
carcinoma
hypernephroma
rcc
clear
cytoplasm
compar
bubbl
cytoplasm
adren
cortex
blood
lake
typic
present
glycogen
present
rcc
absent
adren
lesion
demonstr
pa
without
diastas
cytokeratin
ema
use
ihc
marker
diff
diffus
posit
mem
posit
locat
membran
renal
cell
carcinoma
subtyp
typic
cytogenet
abnorm
see
tabl
ckit
report
posit
almost
papillari
renal
cell
carcinoma
cytoplasm
chromophob
carcinoma
membran
present
clear
cell
carcinoma
mutat
ckit
found
papillari
carcinoma
see
tabl
see
tabl
antibodi
cocktail
antibodi
combin
facilit
evalu
small
lesion
label
greater
number
basal
cell
either
marker
alon
amacr
andor
facilit
identif
small
foci
invas
carcinoma
see
tabl
seen
cytoplasm
unlik
nuclear
pattern
seen
lung
thyroid
carcinoma
c
carcinoid
aris
site
lung
unlik
posit
lung
carcinoid
may
posit
like
express
mucin
histochem
stain
also
use
hcc
neg
cholangiocarcinoma
posit
cyt
cytoplasm
immunoreact
nuc
nuclear
immunoreact
sinusoid
hcc
show
diffus
posit
case
seen
normal
liver
posit
also
seen
focal
nodular
hyperplasia
metastat
carcinoma
show
diffus
posit
case
posit
endotheli
cell
present
throughout
tumor
cell
surround
nest
tumor
cell
seen
hcc
reticulin
stain
help
evalu
fine
needl
aspir
core
needl
biopsi
liver
lesion
hcc
abnorm
pattern
absent
decreas
expand
trabecula
wherea
benign
lesion
show
normal
trabecular
pattern
metastat
carcinoma
usual
distinguish
hcc
frequent
express
rare
express
absenc
bile
canicular
pattern
ceap
absenc
cytoplasm
posit
metastat
carcinoma
liver
often
reliabl
distinguish
cholangiocarcinoma
histolog
appear
immunohistochem
pattern
except
colorect
carcinoma
patient
known
primari
carcinoma
help
compar
two
tumor
see
tabl
tumor
hurthl
cell
chang
may
neg
hbme
b
hurthl
cell
benign
neoplast
posit
nuclear
cytoplasm
c
spindl
cell
may
posit
vimentin
anaplast
thyroid
carcinoma
frequent
neg
thyroglobulin
posit
cyclin
e
low
parathyroid
carcinoma
thyroid
adenoma
follicular
carcinoma
papillari
carcinoma
medullari
carcinoma
variabl
immunoreact
report
anaplast
carcinoma
metastat
carcinoma
thyroid
neg
thyroglobulin
except
lung
carcinoma
calcitonin
new
marker
may
prove
help
distinguish
follicular
carcinoma
posit
adenoma
neg
see
tabl
initi
panel
calretinin
clone
cea
addit
studi
order
difficult
case
antibodi
gener
report
neg
epitheli
mesothelioma
posit
lung
adenocarcinoma
includ
follow
cytokeratin
report
posit
mesothelioma
neg
lung
carcinoma
howev
experi
marker
proven
less
use
one
list
earlier
use
ema
controversi
strong
membran
posit
characterist
epitheli
mesothelioma
wherea
cytoplasm
posit
characterist
adenocarcinoma
less
known
immunophenotyp
pure
sarcomatoid
mesothelioma
spindl
cell
posit
cytokeratin
less
frequent
posit
marker
compar
epithelioid
cell
tumor
occas
resembl
mesothelioma
gener
neg
cytokeratin
notabl
except
case
angiosarcoma
epithelioid
hemangioendothelioma
synovi
sarcoma
epithelioid
sarcoma
leiomyosarcoma
see
tabl
delet
highli
variabl
chang
keratin
immunoreact
accentu
around
nucleu
present
cytoplasm
without
promin
membran
accentu
b
keratin
immunoreact
diffus
present
cytoplasm
membran
accentu
cell
c
immunoreact
nuclear
metastat
adenocarcinoma
gener
neg
except
ovarian
serou
carcinoma
renal
carcinoma
see
tabl
e
metastast
adenocarcinoma
posit
cea
except
see
tabl
tissu
obtain
em
cytogenet
possibl
see
tabl
amyloidosi
greek
amylon
starch
plu
eido
resembl
seen
mani
differ
clinic
set
associ
mani
diseas
pathologist
narrow
differenti
diagnosi
consider
help
guid
clinic
decis
make
find
amyloid
deposit
tissu
similar
find
metastat
carcinoma
lymph
node
set
clinic
inform
eg
histori
physic
examin
radiolog
studi
result
laboratori
test
essenti
arriv
correct
interpret
littl
immunohistochemistri
lot
clinic
judgment
pathologist
help
establish
caus
greater
degre
certainti
find
character
amyloid
deposit
examin
h
e
slide
noncellular
materi
correct
locat
suspect
diseas
tabl
light
chain
detect
best
immunofluoresc
unfix
frozen
tissu
ihc
perform
paraffin
section
less
specif
case
light
chain
diseas
amyloid
posit
amyloid
protein
often
deriv
variabl
domain
wherea
antibodi
detect
common
domain
b
serum
amyloid
protein
detect
unfix
frozen
tissu
amyloid
deposit
orangepink
congo
red
stain
seafoam
green
sulfat
alcian
blue
stain
amyloid
may
appar
stain
howev
bewar
overcal
case
histolog
correl
amyloid
stain
tissu
background
posit
normal
tissu
due
overstain
slide
interpret
posit
control
must
show
appropri
specif
posit
congo
redposit
amyloid
becom
appl
green
color
view
polar
light
may
requir
highqual
polar
built
microscop
lower
qualiti
polar
ie
cut
squar
polar
materi
may
adequ
collagen
silver
h
e
polar
fibrin
polar
may
mimic
amyloid
amyloid
deposit
character
use
immunohistochemistri
immunofluoresc
see
tabl
base
clinic
inform
organ
structur
involv
distribut
amyloid
deposit
tissu
amyloid
also
identifi
use
em
nonbranch
fibril
nm
width
micron
length
firm
diagnosi
alway
possibl
final
diagnosi
base
combin
histolog
immunohistochem
clinic
data
see
tabl
result
studi
incorpor
surgic
patholog
report
follow
inform
includ
type
tissu
studi
formalinfix
fix
tissu
cryostat
section
cytolog
prepar
etc
type
immunoag
use
specif
possibl
exampl
list
keratin
specifi
type
keratin
eg
result
studi
great
enough
detail
allow
interpret
exampl
type
cell
immunoreact
eg
tumor
vs
nontumor
intens
immunoreact
eg
weak
strong
andor
number
cell
immunoreact
eg
focal
vs
diffus
integr
result
final
diagnosi
specifi
whether
confirm
support
diagnosi
make
one
diagnosi
like
other
exclud
one
diagnos
text
continu
page
note
name
common
name
use
refer
marker
name
may
refer
antigen
cd
number
specif
antibodi
rais
antigen
case
one
name
commonli
use
underlin
antibodi
appear
tabl
cd
number
correspond
specif
gene
product
howev
correspond
antigen
posttransl
modif
indic
em
studi
diagnost
renal
biopsi
glomerular
diseas
adenocarcinoma
versu
mesothelioma
see
tabl
difficult
classifi
tumor
tabl
nerv
eg
toxic
druginduc
neuropathi
muscl
biopsi
eg
inclus
bodi
nemalin
myopathi
bullou
skin
diseas
eg
epidermolysi
bullosa
ciliari
dysmorpholog
primari
ciliari
dyskinesia
kartagen
syndrom
endomyocardi
biopsi
eg
adriamycin
toxic
amyloid
nemalin
myopathi
liver
biopsi
microvesicular
fat
acut
fatti
liver
pregnanc
small
bowel
biopsi
look
pathogen
eg
whippl
diseas
congenit
inherit
metabol
diseas
eg
ceroid
lipofuscinos
prion
diseas
method
ultrastructur
detail
tissu
lost
rapidli
therefor
fresh
tissu
must
fix
rapidli
well
em
tissu
usual
fix
special
fix
em
preserv
lipid
glycogen
eg
paraformaldehyd
glutaraldehyd
cacodyl
buffer
ph
place
small
fragment
tissu
drop
fix
cut
surfac
cut
tissu
multipl
tini
fragment
greater
cm
dimens
place
tissu
vial
fix
shake
vial
make
sure
tissu
fragment
cover
fix
note
tissu
small
biopsi
found
nondiagnost
h
e
tissu
save
em
retriev
examin
light
microscopi
separ
electron
microscopi
report
usual
issu
result
incorpor
final
diagnosi
rhomboid
rodshap
spicul
crystal
regular
latttic
pattern
characterist
cytoplasm
crystal
compos
monocarboxyl
transport
chaperon
protein
found
mani
cell
type
specif
tumor
cytogenet
x
creat
fusion
protein
ihc
posit
well
rare
pediatr
renal
tumor
transloc
nuclear
immunoreact
present
tumor
normal
tissu
histo
crystal
pa
diastas
posit
tumor
also
keratin
posit
desmosom
filament
cytokeratin
mesothelioma
meningioma
synovi
sarcoma
epithelioid
sarcoma
melanosom
variou
stage
develop
indic
melaninform
cell
type
abnorm
pleomorph
melanosom
may
present
melanoma
desmoplast
melanoma
lack
melanosom
ihc
may
absent
nonepithelioid
melanoma
epitop
present
immatur
melanosom
premelanosom
specif
structur
melanosom
also
seen
clear
cell
sarcoma
pigment
schwannoma
pecoma
rare
tumor
matur
form
taken
melanophag
keratinocyt
carcinoma
specif
featur
present
cell
lack
cellular
junction
pauciti
cytoplasm
organel
ihc
lca
lca
may
absent
anaplast
lymphoma
tumor
ema
keratin
type
specif
diagnost
featur
cell
type
eg
neural
smooth
muscl
striat
muscl
welldevelop
desmosom
ihc
may
help
identifi
specif
type
keratin
neg
except
synovi
sarcoma
epithelioid
sarcoma
rare
type
amyloid
nonbranch
fibril
nm
width
micron
length
may
present
associ
plasma
cell
tumor
medullari
carcinoma
thyroid
alzheim
diseas
isol
find
primari
amyloidosi
ihc
use
identifi
specif
type
amyloid
eg
lambda
kappa
chain
microglobulin
calcitonin
tau
bronchioloalveolar
carcinoma
lung
bal
lamellar
surfact
myelinlik
granul
supranuclear
cytoplasm
typic
type
ii
pneumocyt
claralik
electrondens
granul
supranuclear
cytoplasm
intranuclear
inclus
compris
parallel
microtubular
array
featur
also
seen
metastat
bal
cytogenet
carcinoma
less
like
associ
smoke
fewer
cytogenet
chang
bronchioloalveolar
carcinoma
adenocarcinoma
featur
bal
like
respond
iressa
compar
lung
carcinoma
due
specif
mutat
egfr
mucin
bal
intranuclear
inclus
gener
lack
em
featur
cytogenet
ew
fusion
protein
ihc
dens
core
granul
dens
core
granul
vesicl
bound
singl
membran
dens
center
nm
cytoplasm
organel
involv
regul
exocytosi
cell
product
exampl
pancreat
beta
cell
insulin
angular
crystallin
inclus
pheochromocytoma
epinephrin
norepinephrin
larg
pleomorph
often
clear
partial
fill
carcinoid
foregut
small
round
midgut
larger
pleomorph
hindgut
mix
found
tumor
neuron
neuroendocrin
origin
vesicl
compris
granin
predominantli
chromogranin
chromogranin
b
secretogranin
ii
variou
peptid
hormon
transmitt
atp
biogen
amin
ihc
chromogranin
specif
specif
product
tumor
also
detect
note
prostat
cancer
breast
cancer
also
show
strong
chromogranin
posit
mistaken
neuroendocrin
tumor
particularli
metastat
site
weibelpalad
bodi
frequent
absent
tumor
aris
endotheli
cell
eg
angiosarcoma
ihc
marker
sensit
detect
endotheli
deriv
membran
form
pselectin
tubul
contain
fviii
ihc
vascular
marker
fviii
homogen
cell
popul
character
lack
special
featur
larg
pool
glycogen
organel
extracellular
matrix
variabl
number
neurosecretori
granul
cell
process
cytogenet
ew
fusion
protein
less
common
variant
ihc
also
present
less
specif
histo
pa
diastas
detect
glycogen
current
use
diagnosi
numer
lysosom
fill
tubular
vesicular
amorph
materi
phagosom
granul
correl
granular
cytoplasm
redupl
basal
lamina
surround
group
cell
ihc
inhibin
calretinin
birbeck
granul
rodor
tenni
racketshap
structur
variabl
length
central
period
striat
lamella
may
serv
reservoir
langerin
transmembran
type
ii
lectin
endosom
recycl
compart
ihc
langerin
lamel
scrolllik
membran
pattern
granul
variabl
size
cytogenet
characterist
chang
alveolar
embryon
type
ihc
muscl
marker
desmin
basal
lamina
promin
often
redupl
luse
bodi
long
space
collagen
extracellular
myelin
figur
long
cell
process
wrap
around
collagen
may
rare
melanosom
melanot
schwannoma
cytogenet
delet
inactiv
ihc
frozen
tissu
use
stain
antibodi
detect
antigen
frozen
tissu
enzym
studi
muscl
biopsi
save
tissu
dna
rna
studi
specimen
question
lymphoprolif
disord
sarcoma
unusu
tumor
muscl
biopsi
method
small
approxim
cm
portion
tissu
place
clean
specimen
contain
moisten
small
amount
normal
salin
frozen
specimen
snap
frozen
use
liquid
nitrogen
dri
ice
store
result
studi
frozen
tissu
usual
incorpor
surgic
patholog
report
like
immunoperoxidas
studi
immunofluoresc
detect
antigen
tissu
howev
amplif
signal
use
better
suit
precis
local
antigenantibodi
complex
tissu
determin
deposit
pattern
immun
complex
eg
linear
vs
granular
thu
use
investig
diseas
relat
immun
complex
deposit
glomerular
diseas
bullou
diseas
skin
tissu
may
snap
frozen
see
instruct
earlier
store
special
fix
specimen
frozen
special
care
must
taken
ensur
biopsi
kept
moist
seal
contain
direct
use
antibodi
detect
antigen
patient
tissu
indirect
use
control
tissu
detect
antibodi
eg
antibm
patient
serum
indic
skin
biopsi
eg
lupu
pemphigu
pemphigoid
dermat
herpetiformi
diagnost
nontranspl
renal
biopsi
transplant
renal
biopsi
identif
amyloid
cardiac
biopsi
evalu
vascul
nerv
biopsi
method
tissu
must
submit
fresh
result
result
examin
usual
incorpor
surgic
patholog
report
sle
lupu
band
test
linear
granular
stain
along
dermal
epiderm
junction
multipl
immunoreact
case
commonli
igg
less
often
igm
specif
increas
number
posit
immunoreact
uninvolv
sunexpos
skin
show
posit
patient
activ
system
lupu
uninvolv
skin
patient
discoid
lupu
usual
neg
test
herp
gestationi
perilesion
skin
show
linear
bm
zone
sometim
igg
dermat
herpetiformi
granular
iga
tip
dermal
papilla
uninvolv
skin
pemphigu
igg
epiderm
cell
creat
netlik
pattern
pemphigu
vulgari
split
basal
cell
layer
creat
tombston
appear
row
basal
cell
base
vesicl
pemphigu
foliaceu
relat
disord
split
occur
near
granular
cell
layer
pemphigoid
ig
along
basement
membran
cell
indirect
reveal
antibm
antibodi
molecular
genet
patholog
newest
subspeci
patholog
board
certif
molecular
diagnost
incorpor
mani
type
techniqu
investig
genet
alter
cell
virus
eg
southern
blot
pcr
analysi
fish
applic
three
main
area
inherit
diseas
identif
inherit
diseas
eg
cystic
fibrosi
hemochromatosi
factor
v
leiden
prothrombin
fragil
x
syndrom
identif
gene
confer
suscept
diseas
eg
microsatellit
instabl
msi
infecti
diseas
detect
organ
identif
specif
organ
quantit
viral
infect
eg
hiv
viral
load
identif
specif
genet
alter
associ
tumor
identif
gene
mutat
associ
suscept
treatment
eg
egfr
mutat
lung
cancer
ckit
mutat
gist
identif
clonal
hematolymphoid
prolifer
detect
minim
residu
diseas
treat
ment
studi
especi
help
hematolymphoid
prolifer
difficult
classifi
frequent
characterist
rearrang
occur
mani
disord
unlik
cytogenet
cell
need
viabl
howev
prefer
nucleic
acid
rel
intact
southern
blot
rnabas
pcr
rtpcr
assay
best
perform
fresh
frozen
tissu
formalinfix
paraffinembed
tissu
amen
dnabas
pcr
assay
fix
eg
bouin
caus
extens
breakag
dna
may
preclud
genet
analysi
tissu
bcell
prolifer
clonal
rearrang
immunoglobulin
heavi
light
chain
gene
specif
transloc
tcell
prolifer
rearrang
method
submit
tissu
fresh
frozen
tissu
eg
snap
frozen
tissu
well
fluid
may
use
cytolog
prepar
use
fish
paraffin
block
also
use
result
usual
either
report
separ
incorpor
surgic
patholog
report
cytogenet
studi
demonstr
use
sever
area
import
patholog
tumor
classif
particularli
sarcoma
eg
ewe
sarcoma
synovi
sarcoma
lymphoma
leukemia
kidney
tumor
brain
tumor
unusu
tumor
benign
vs
malign
lesion
reactiv
mesotheli
cell
vs
mesothelioma
lipoma
vs
liposarcoma
prognosi
neuroblastoma
oligodendroglioma
multipl
myeloma
chronic
lymphocyt
leukemia
treatment
amplif
predict
respons
herceptin
research
transloc
common
mani
tumor
usual
identifi
gene
import
pathogenesi
tumor
cell
may
cultur
perform
complet
karyotyp
analysi
tissu
analyz
specif
chromosom
alter
fluoresc
situ
hybrid
fish
fish
studi
perform
cultur
cell
cytolog
specimen
touch
prepar
paraffinembed
tissu
karyotyp
analysi
soft
tissu
tumor
mesothelioma
tissu
pleural
fluid
unusu
tumor
poorli
differenti
tumor
subcutan
lipoma
cm
unusu
gross
appear
deepseat
lipoma
subfasci
intramuscular
intraabdomin
retroperiton
clinic
appar
cord
tumor
unusu
uterin
mass
fish
oligodendroglioma
neuroblastoma
method
submit
tissu
tissu
karyotyp
must
fresh
viabl
rel
steril
howev
tissu
may
submit
even
handl
strictli
steril
condit
contamin
usual
problem
specimen
held
overnight
tissu
minc
cm
cube
steril
specimen
contain
cover
cultur
medium
held
overnight
refriger
fluid
may
also
submit
analysi
especi
pleural
effus
suspicion
mesothelioma
result
cytogenet
analysi
incorpor
final
diagnosi
report
separ
tabl
text
continu
page
isochromosom
delet
encod
ckit
protooncogen
transmembran
receptor
protein
tyrosin
kinas
activ
mutat
may
render
kit
independ
ligand
scf
stem
cell
factor
mutat
protein
may
may
respond
therapi
imatinib
wildtyp
kit
kit
mutat
juxtamembran
domain
intracellular
segment
transmembran
tyrosin
kinas
domain
found
gist
sensit
imatinib
tumor
type
associ
mutat
enzymat
domain
alter
protein
gener
sensit
imatinib
overexpress
protein
detect
ihc
gefitinib
iressa
tyrosin
kinas
inhibitor
effect
small
subset
lung
adenocarcinoma
specif
activ
mutat
egfr
ihc
egfr
help
identifi
carcinoma
like
respond
treatment
addit
inform
specif
gene
see
onlin
mendelian
inherit
man
omim
wwwncbinlmnihgov
imatinib
mesyl
gleevec
glivec
small
molecul
tyrosin
kinas
inhibitor
may
use
treatment
tumor
overexpress
tyrosin
kinas
bcrabl
tyrosin
kinas
cml
ph
kit
tyrosin
kinas
gist
system
mastocytosi
type
aml
pdgfr
kinas
cmml
chronic
eosinophil
leukemia
rare
case
gist
kit
protein
encod
ckit
protooncogen
transmembran
receptor
protein
tyrosin
kinas
activ
mutat
may
render
kit
independ
ligand
scf
stem
cell
factor
mutat
protein
may
may
respond
therapi
imatinib
wildtyp
kit
kit
mutat
juxtamembran
domain
intracellular
segment
transmembran
tyrosin
kinas
domain
found
gist
sensit
imatinib
tumor
type
associ
mutat
enzymat
domain
alter
protein
gener
sensit
imatinib
addit
inform
specif
gene
see
onlin
mendelian
inherit
man
omim
wwwncbinlmnihgov
follow
featur
suggest
hereditari
suscept
cancer
two
close
rel
side
famili
cancer
evid
autosom
domin
transmiss
earli
develop
cancer
patient
rel
gener
year
age
multipl
primari
cancer
multipl
type
cancer
unusu
patholog
featur
tumor
tabl
constel
tumor
suggest
specif
syndrom
tabl
pathologist
aid
detect
hereditari
carcinoma
awar
type
patholog
characterist
carcinoma
associ
syndrom
patient
germlin
mutat
import
identifi
order
screen
patient
common
tumor
compon
diseas
consid
prophylact
surgeri
prevent
intervent
offer
screen
famili
member
risk
genet
counsel
text
continu
page
colon
carcinoma
like
overal
right
side
poorli
differenti
medullari
mucin
signet
ring
undifferenti
promin
lymphocyt
infiltr
ihc
use
detect
absenc
usual
due
germlin
mutat
due
germlin
mutat
epigenet
chang
methyl
less
commonli
somat
mutat
mani
patient
ihc
sensit
msi
specif
msi
test
also
use
although
sporad
form
cancer
gener
far
outnumb
case
associ
germlin
mutat
case
appear
site
carcinoma
highli
suggest
known
syndrom
investig
may
warrant
flow
cytomet
analyz
popul
thousand
dissaggreg
cell
pass
stationari
detector
cell
size
cytoplasm
granular
measur
well
dna
content
presenc
absenc
immunohistochem
marker
ad
cell
suspens
newer
techniqu
analyz
three
featur
simultan
divid
cell
uniqu
popul
dna
content
use
determin
number
cell
sphase
measur
prolifer
sphase
fraction
cell
visual
techniqu
one
must
sure
submit
lesion
tissu
hydatidiform
mole
complet
diploid
partial
triploid
carcinoma
dna
ploidi
sphase
report
prognost
signific
carcinoma
eg
colon
breast
prostat
routin
perform
institut
use
oncologist
indic
cell
surfac
marker
analysi
method
submit
tissu
singl
cell
suspens
necessari
analysi
fresh
tissu
cell
must
viabl
fresh
tissu
approxim
cm
place
specimen
contain
kept
moist
hbss
tissu
held
overnight
refriger
formalinfix
paraffinembed
section
may
also
use
dna
ploidi
analysi
hedley
method
although
result
satisfactori
due
nuclear
fragment
result
usual
incorpor
final
surgic
patholog
report
cytolog
prepar
surgic
specimen
often
add
addit
inform
intraop
diagnosi
touch
prep
smear
especi
valuabl
infecti
case
avoid
contamin
cryostat
aerosol
infecti
agent
neuropatholog
case
diagnosi
perform
cytogenet
fish
analysi
tumor
excel
cytolog
detail
especi
lymphoma
papillari
carcinoma
thyroid
special
stain
stain
microorgan
perform
day
cytolog
smear
specimen
critic
ill
patient
submit
airdri
smear
infecti
case
stain
unfix
materi
may
constitut
hazard
laboratori
personnel
fat
dissolv
routin
process
demonstr
fat
stain
air
dri
slide
genet
studi
fish
touch
prepar
nuclei
intact
unlik
tissu
section
partial
nuclei
present
featur
make
prepar
superior
techniqu
fish
imag
analysi
compar
cytolog
prepar
correspond
surgic
specimen
alway
use
exercis
learn
compar
morpholog
techniqu
specimen
radiograph
often
prefer
patient
radiograph
perman
record
radiograph
kept
case
radiograph
specimen
may
reveal
detail
underli
process
eg
fewer
structur
may
present
complic
appear
may
signific
time
interv
patient
radiograph
surgic
excis
radiograph
often
indic
import
site
examin
histolog
tumor
invas
rib
microcalcif
breast
biopsi
specimen
radiograph
confirm
clinic
lesion
remov
tumor
bone
cartilag
tumor
invad
bone
avascular
necrosi
bioprosthet
heart
valv
document
degre
calcif
breast
biopsi
mastectomi
perform
mammograph
lesion
locat
grossli
paraffin
block
breast
tissu
radiograph
microcalcif
seen
specimen
radiographi
histolog
section
identifi
prior
process
clip
place
core
needl
biopsi
also
easili
identifi
calcif
dissolv
formalin
sever
day
demonstr
calcif
import
eg
mammograph
detect
calcif
prefer
process
tissu
within
day
process
delay
tissu
store
ethanol
radiograph
equip
avail
radiolog
depart
patholog
depart
specimen
may
place
piec
wax
paper
keep
surfac
clean
lie
film
specimen
radiograph
decalcif
calcium
remov
best
result
obtain
fresh
undecalcifi
specimen
lung
inflat
prior
radiographi
specimen
small
two
exposur
differ
set
differ
angl
may
use
lead
sheet
use
allow
two
exposur
one
piec
film
film
dark
overexpos
exposur
high
lower
set
tri
film
light
ie
unexpos
exposur
low
higher
set
indic
special
inject
techniqu
radiocontrast
media
avail
unusu
specimen
eg
recipi
lung
pulmonari
hypertens
vascular
ectasia
bowel
octreotid
sentinel
node
label
compound
sometim
use
local
certain
type
tumor
gener
neuroendocrin
sentinel
lymph
node
patient
inject
isotop
prior
surgeri
surgeon
use
hand
held
probe
identifi
label
tissu
amount
radioact
tissu
small
gener
pose
hazard
pathologist
handl
tissu
need
special
dispos
method
howev
patholog
depart
consult
radiat
safeti
depart
ensur
appropri
handl
tissu
case
gross
lesion
present
correspond
area
octreotid
uptak
specimen
imag
use
gamma
camera
result
radiograph
document
gross
descript
inform
gain
radiograph
incorpor
surgic
patholog
report
patholog
depart
uniqu
resourc
research
need
human
tissu
pathologist
play
key
role
patient
advoc
diagnostician
order
provid
appropri
human
tissu
biolog
research
hospit
polici
allow
releas
tissu
research
would
otherwis
discard
therefor
tissu
never
provid
research
necessari
tissu
taken
diagnosi
tissu
primari
diagnost
breast
biopsi
open
lung
biopsi
without
gross
lesion
must
given
away
best
interest
patient
pathologist
evalu
specimen
rather
tissu
given
away
nonpathologist
awar
need
diagnosi
indic
request
research
obtain
permiss
hospit
institut
review
board
irb
patient
must
provid
specif
consent
case
patient
identif
need
remov
specimen
investig
infecti
diseas
cultur
complementari
investig
histolog
section
tabl
perform
aspir
swab
fluid
tissu
requir
surgic
excis
tissu
cultur
amplifi
number
organ
present
allow
recogn
organ
may
rare
seen
tissu
section
specif
organ
identifi
test
drug
suscept
categori
organ
recogn
specif
identif
may
possibl
organ
cultur
mani
organ
identifi
grow
cultur
requir
long
cultur
time
eg
tb
may
difficult
exclud
contamin
posit
cultur
morpholog
evid
inflammatori
respons
provid
evid
clinic
infect
locat
infect
may
diagnost
import
eg
cellul
vs
necrot
fasciiti
superfici
colon
devit
tissu
vs
deep
infect
involv
viabl
tissu
use
special
studi
pcr
molecular
assay
may
warrant
tissu
pattern
injuri
indic
potenti
organ
despit
lack
cultur
evid
andor
lack
organ
seen
tissu
section
suspect
infecti
process
either
clinic
data
frozen
section
suspect
sarcoid
exclud
infecti
process
method
tissu
kept
steril
possibl
sutur
remov
kit
conveni
sourc
steril
scissor
forcep
serial
section
specimen
determin
focal
lesion
place
repres
section
steril
specimen
contain
make
sure
retain
duplic
piec
tissu
histolog
label
patient
name
unit
number
patient
physician
type
specimen
collect
date
time
collect
requir
joint
commiss
accredit
result
gener
report
microbiolog
laboratori
commun
microbiolog
laboratori
staff
essenti
correl
histolog
result
microbiolog
result
specimen
report
result
cultur
surgic
specimen
usual
report
separ
report
